- Full Year 2024 Terumo Corp Earnings Presentation TranscriptMay 14, 2024
- Q3 2024 Terumo Corp Earnings Presentation TranscriptFeb 07, 2024
- Q2 2024 Terumo Corp Earnings Presentation TranscriptNov 14, 2023
- Q1 2024 Terumo Corp Earnings Presentation TranscriptAug 09, 2023
- Full Year 2023 Terumo Corp Earnings Call TranscriptMay 15, 2023€14.2 (+0.71%)Earnings
- Q3 2023 Terumo Corp Earnings Call TranscriptFeb 09, 2023€13.3 (-1.48%)Earnings
- Q2 2023 Terumo Corp Earnings Call TranscriptNov 10, 2022€14.7 (-0.68%)Earnings
- Q1 2023 Terumo Corp Earnings Call TranscriptAug 09, 2022€15.4 (-3.75%)Earnings
- Full Year 2022 Terumo Corp Earnings Call TranscriptMay 12, 2022€13.6 (-2.86%)Earnings
- Q3 2022 Terumo Corp Earnings Call TranscriptFeb 09, 2022€15.75 (+3.06%)Earnings
- Terumo Corp New Growth Strategy Briefing TranscriptDec 16, 2021
- Q2 2022 Terumo Corp Earnings Call TranscriptNov 04, 2021€19.5 (+2.63%)Earnings
- Q1 2022 Terumo Corp Earnings Call TranscriptAug 04, 2021€16.3 (-1.21%)Earnings
- Full Year 2021 Terumo Corp Earnings Call TranscriptMay 12, 2021€15.2 (-1.30%)Earnings
- Q3 2021 Terumo Corp Earnings Call TranscriptFeb 04, 2021€17.1 (+4.27%)Earnings
- Q2 2021 Terumo Corp Earnings Call TranscriptNov 05, 2020€16 (+0.63%)Earnings
- Q1 2021 Terumo Corp Earnings Call TranscriptAug 06, 2020€15.9 (-1.24%)Earnings
- Full Year 2020 Terumo Corp Earnings Call TranscriptMay 18, 2020€16.6 (+7.79%)Earnings
- Q3 2020 Terumo Corp Earnings Call TranscriptFeb 06, 2020€16.6 (+2.47%)Earnings
- Q2 2020 Terumo Corp Earnings Presentation TranscriptNov 07, 2019
- Q1 2020 Terumo Corp Earnings Call TranscriptAug 08, 2019€13.21 (+2.88%)Earnings
- Full Year 2019 Terumo Corp Earnings Presentation TranscriptMay 09, 2019
Full Year 2021 Terumo Corp Earnings Call Transcript
I am the CFO, Muto. I will now explain the results for the fiscal year ended March 2021. First, here is a summary of highlights of the results. Sales revenue for the year saw steady recovery, thanks to the return of demand despite remaining effects of COVID-19 in the second half on the Cardiac and Vascular Company. In the General Hospital and Blood and Cell Technologies companies, products related to infection prevention and COVID-19 treatment contributed to increased sales revenue and to stability for the group as a whole. Although some impact remained, the most recent stand-alone fourth quarter results showed our highest ever Q4 sales revenue.
In adjusted operating profit, there was some negative gross profit impact from volume-based procurement in China and production adjustment with TIS products and some acceleration of expenditures due to easing of restrictions on movement. However, recovery of sales revenue enabled restoration of profit to just a single-digit year-on-year decrease. Due to this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)